Kent C Taylor

US Patent:

20040053263, Mar 18, 2004

Filed:

Jan 30, 2003

Appl. No.:

10/356736

Inventors:

Maria Abreu - Pacific Palisades CA, US
Kent Taylor - Ventura CA, US
Jerome Rotter - Los Angeles CA, US
Huiying Yang - Cerritos CA, US
Kazuhito Sugimura - Niigata, JP
Stephan Targan - Santa Monica CA, US

International Classification:

C12Q001/68

US Classification:

435/006000

Abstract:

The present invention provides a method of diagnosing or predicting susceptibility to a clinical subtype of Crohn's disease characterized by fibrostenosing disease by determining the presence or absence in an individual of a fibrostenosis-predisposing allele linked to a NOD2/CARD15 locus, where the presence of the fibrostenosis-predisposing allele is diagnostic of or predictive of susceptibility to the clinical subtype of Crohn's disease characterized by fibrostenosing disease. In a method of the invention, the clinical subtype of Crohn's disease can be, for example, characterized by fibrostenosing disease independent of small bowel involvement. The invention also provides a method of optimizing therapy in an individual by determining the presence or absence in the individual of a fibrostenosis-predisposing allele linked to a NOD2/CARD15 locus, diagnosing individuals in which the fibrostenosis-predisposing allele is present as having a fibrostenosing subtype of Crohn's disease, and treating the individual having a fibrostenosing subtype of Crohn's disease based on the diagnosis.

US Patent:

20100021917, Jan 28, 2010

Filed:

Feb 14, 2008

Appl. No.:

12/527376

Inventors:

Jerome I. Rotter - Los Angeles CA, US
Kent D. Taylor - Ventura CA, US
Stephan R. Targan - Santa Monica CA, US

Assignee:

CEDARS-SINAI MEDICAL CENTER - Los Angeles CA

International Classification:

C12Q 1/68

US Classification:

435 6

Abstract:

This invention provides methods of diagnosing or predicting susceptibility to inflammatory bowel disease by determining the presence or absence of genetic variants. In one embodiment, a the invention is practiced by determining the presence or absence of NOD2 variants in an individual where the presence of NOD2 variants are indicative of susceptibility to Crohn's Disease in the individual. In another embodiment, the invention further determines the presence or absence of TLR8 variants where the presence of TLR8 variants are inflammatory bowel disease in female individuals. In another embodiment, the invention further determines the presence or absence of TR2 variant P631H where the presence of TLR2 variant P631H is indicative of susceptibility to Crohn's Disease.

US Patent:

20100055700, Mar 4, 2010

Filed:

Feb 28, 2008

Appl. No.:

12/528668

Inventors:

Stephan R. Targan - Santa Monica CA, US
Jerome I. Rotter - Los Angeles CA, US
Kent D. Taylor - Ventura CA, US

Assignee:

CEDARS-SINAI MEDICAL CENTER - Los Angeles CA

International Classification:

C12Q 1/68

US Classification:

435 6

Abstract:

This invention provides methods of diagnosing or predicting susceptibility or protection against Inflammatory Bowel Disease in an individual by determining the presence or absence of genetic variants in the genes for IL-12, IL-23, and/or IL-17 receptors. In one embodiment, a method of the invention is practiced by determining the presence or absence of risk and/or protective haplotypes of IL-12, IL-23, and/or IL-17 receptors.

US Patent:

20100130600, May 27, 2010

Filed:

Mar 28, 2008

Appl. No.:

12/594143

Inventors:

Mark O. Goodarzi - Los Angeles CA, US
Kent D. Taylor - Ventura CA, US
Maren T. Scheuner - Manhattan Beach CA, US
Xiuqing Guo - Santa Monica CA, US
Prediman K. Shah - Los Angeles CA, US
Jerome I. Rotter - Los Angeles CA, US

Assignee:

CEDARS-SINAI MEDICAL CENTER - Los Angeles CA

International Classification:

C12Q 1/68
A61K 31/366

US Classification:

514460, 435 6

Abstract:

The invention provides methods of treating and prognosing atherosclerosis and lipid response to statin treatment by determining the presence or absence of haplotypes at the lipoprotein lipase locus. In one embodiment, the invention is practiced by evaluating the prognosis of vascular grafts in an individual undergoing statin treatment by determining the presence or absence of haplotypes at the lipoprotein locus.

US Patent:

20100184050, Jul 22, 2010

Filed:

Apr 25, 2008

Appl. No.:

12/597710

Inventors:

Jerome I. Rotter - Los Angeles CA, US
Kent D. Taylor - Ventura CA, US
Esther A. Torres - San Juan CA, US

Assignee:

CEDARS-SINAI MEDICAL CENTER - Los Angeles CA

International Classification:

C12Q 1/68

US Classification:

435 6

Abstract:

This invention provides methods of diagnosis and treatment of inflammatory bowel disease. In one embodiment, the invention provides methods of diagnosing and/or predicting susceptibility for inflammatory bowel disease in the Puerto Rican population by determining the presence or absence of a risk variant at the HPS1 locus. In another embodiment, the invention further provides methods of diagnosing and/or predicting protection against inflammatory bowel disease by determining the presence or absence of a protective variant at the IRF1 locus. In another embodiment, the presence in an individual of a risk variant at the CARD8 locus is diagnostic of susceptibility to Crohn's Disease in a Puerto Rican individual. In another embodiment, the presence of a risk variant at the TLR-9 locus in an individual is diagnostic of susceptibility to Crohn's Disease.

US Patent:

20100190162, Jul 29, 2010

Filed:

Feb 26, 2008

Appl. No.:

12/528055

Inventors:

Jerome I. Rotter - Los Angeles CA, US
Kent D. Taylor - Ventura CA, US
Marla Dubinsky - Los Angeles CA, US
Stephan R. Targan - Santa Monica CA, US

Assignee:

CEDARS-SINAI MEDICAL CENTER - Los Angeles CA

International Classification:

C12Q 1/68

US Classification:

435 6

Abstract:

This invention provides methods of diagnosing or predicting susceptibility to Inflammatory Bowel Disease by determining the presence or absence of genetic variants in the TL1A gene. In one embodiment, a method of the invention is practiced by determining the presence or absence of TL1A production following Fc-gamma-R activation. In another embodiment, the invention provides methods of treatment of inflammatory bowel disease by inhibition of TL1A.

US Patent:

20100240043, Sep 23, 2010

Filed:

Oct 20, 2008

Appl. No.:

12/675718

Inventors:

Jerome I. Rotter - Los Angeles CA, US
Kent D. Taylor - Ventura CA, US
Stephan R. Targan - Santa Monica CA, US
Dermot P. McGovern - Los Angeles CA, US
Ling Mei - Pasadena CA, US
Xiaowen Su - Beverly Hills CA, US

Assignee:

CEDARS-SINAI MEDICAL CENTER - Los Angeles CA

International Classification:

C12Q 1/68

US Classification:

435 6

Abstract:

The present invention relates to methods of diagnosing susceptibility to Inflammatory Bowel Disease and subtypes of Inflammatory Bowel Disease. In one embodiment, the present invention provides a method of diagnosing susceptibility to Inflammatory Bowel Disease by determining the presence of one or more risk variants at the DR3 locus, GATA3 locus, SIN(EFS) locus, BTLA locus, LIGHT locus and MAGE locus.

US Patent:

20110111418, May 12, 2011

Filed:

Jun 23, 2009

Appl. No.:

12/999605

Inventors:

Shannon L. Rhodes - Los Angeles CA, US
Kent D. Taylor - Ventura CA, US
Beate Ritz - Los Angeles CA, US

Assignee:

CEDARS-SINAI MEDICAL CENTER - Los Angeles CA
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA

International Classification:

C12Q 1/68

US Classification:

435 6

Abstract:

A collection of genetic variants having susceptability to, or protection from, Parkinson's Disease is provided. The variants are useful in method of diagnosing, prognosing, and treating Parkinson's Disease and related conditions